Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 9/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | MAP2 | P11137 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.32 |
| ▸ | CDK8 | P49336 | 1/20 | 0.32 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.32 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1103640 | 0.99 | PDK2 (0.40) | PDK2TNFALOX5PIK3CDMAP2 | |
| SCHEMBL1103678 | 0.97 | PDK2 (0.39) | PDK2TNFALOX5PIK3CDMAP2 | |
| SCHEMBL1103641 | 0.96 | PDK2 (0.38) | PDK2TNFALOX5PIK3CDMAP2 | |
| SCHEMBL1103624 | 0.96 | PDK2 (0.40) | PDK2TNFPIK3CDPIK3CAMAPK10 | |
| SCHEMBL1103644 | 0.95 | PDK2 (0.40) | PDK2TNFPIK3CD | |
| SCHEMBL1102799 | 0.94 | PDK2 (0.42) | PDK2TNFALOX5PIK3CDMAP2 | |
| SCHEMBL1102593 | 0.94 | PDK2 (0.42) | PDK2TNFALOX5PIK3CDMAP2 | |
| SCHEMBL1102790 | 0.93 | PDK2 (0.40) | PDK2TNFALOX5PIK3CDMAP2 | |
| SCHEMBL1102613 | 0.93 | PDK2 (0.40) | PDK2TNFALOX5PIK3CDMAP2 | |
| SCHEMBL1103688 | 0.93 | CYP17A1 (0.40) | PDK2TNFALOX5MAPK10CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-8153279-B2 | Organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2012-04-10 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100033083-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | ORMDL3, OCIAD2, OCIAD1 | PDK2 1930/4885TNF 3803/4885ALOX5 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.